- Home
- VGM vs LAB Comparison
VGM vs LAB Comparison
Compare VGM & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGM
- LAB
- Stock Information
- Founded
- VGM 1992
- LAB 1999
- Country
- VGM United States
- LAB United States
- Employees
- VGM N/A
- LAB N/A
- Industry
- VGM Trusts Except Educational Religious and Charitable
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- VGM Finance
- LAB Industrials
- Exchange
- VGM Nasdaq
- LAB Nasdaq
- Market Cap
- VGM 522.8M
- LAB 473.2M
- IPO Year
- VGM N/A
- LAB 2011
- Fundamental
- Price
- VGM $9.71
- LAB $1.30
- Analyst Decision
- VGM
- LAB Buy
- Analyst Count
- VGM 0
- LAB 2
- Target Price
- VGM N/A
- LAB $2.50
- AVG Volume (30 Days)
- VGM 186.2K
- LAB 1.3M
- Earning Date
- VGM 01-01-0001
- LAB 10-29-2025
- Dividend Yield
- VGM 4.34%
- LAB N/A
- EPS Growth
- VGM N/A
- LAB N/A
- EPS
- VGM 0.01
- LAB N/A
- Revenue
- VGM N/A
- LAB $172,271,000.00
- Revenue This Year
- VGM N/A
- LAB N/A
- Revenue Next Year
- VGM N/A
- LAB N/A
- P/E Ratio
- VGM $988.00
- LAB N/A
- Revenue Growth
- VGM N/A
- LAB 76.33
- 52 Week Low
- VGM $8.15
- LAB $0.92
- 52 Week High
- VGM $10.07
- LAB $2.32
- Technical
- Relative Strength Index (RSI)
- VGM 67.17
- LAB 53.08
- Support Level
- VGM $9.52
- LAB $1.20
- Resistance Level
- VGM $9.56
- LAB $1.31
- Average True Range (ATR)
- VGM 0.06
- LAB 0.07
- MACD
- VGM 0.00
- LAB 0.00
- Stochastic Oscillator
- VGM 93.20
- LAB 68.75
About VGM Invesco Trust for Investment Grade Municipals (DE)
Invesco Trust for Investment Grade Municipals is active in the financial services sector. Its investment objective is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.